Barry Allen
Chairman, President, and Chief Executive Officer

Mr. Allen brings 20 years of medical technology management experience to Urodynamix. Most recently, he was Entrepreneur-in-Residence at Ventures West Management Inc., a venture capital investor focused on North American life science and technology firms.

From March 1999 to February 2004, Mr. Allen was President and CEO of VSM MedTech Ltd. During his tenure at VSM, the company grew from five to over 150 employees and evolved from a research and development company into a world-class manufacturer and marketer of medical products. Under Mr. Allen’s leadership, VSM generated sales of approximately $20 million in 2003. He successfully raised more than $65 million in capital and led VSM’s migration from the CDNX Venture Exchange to the Toronto Stock Exchange with a corresponding increase in market capitalization from $2 million to a high of approximately $400 million.

Mr. Allen serves on a number of for-profit and charity boards including Medical Ventures Corp (TSX-V:MEV), LifeSciences British Columbia and the Manning Innovation Awards. He is Chairman of the BC Excels Professional Skills Program and a co-founder of the Western Canadian Pediatric AIDS Foundation. In 2003, he was recognized as one of “Canada’s Top 40 under 40” by The Globe and Mail and The Report on Business.

Paul Geyer, P.Eng.
Director

Mr. Geyer is the Chairman and CEO of Medical Ventures Corp., a medical devices firm that specializes in products for the quickly growing cardiovascular and surgical marketplace. Mr. Geyer was formerly the President of Mitroflow International Inc. (later named Sulzer Mitroflow Corp.) from 1991 to 2001, where he was instrumental in commercializing the company’s tissue heart valve products; growing the firm from nine to over 120 employees; and selling the company in 1999 to Sulzer Medica of Switzerland.

In 1998, Mr. Geyer received the Entrepreneur of the Year Award from the Richmond Chamber of Commerce. In 1999, he was named by Business in Vancouver as one of its “Top 40 Under 40,” an award honouring the top young business people in British Columbia. In the same year, Business in Vancouver named his company, Mitroflow International Inc. as one of “British Columbia's 50 Fastest Growing Companies.”

Mr. Geyer is an active angel investor in local technology and life science companies and is on the board of directors for several private and public companies. He served previously on the board of directors for the Medical Device Development Centre and MEDEC (Medical Devices Canada), which represents medical device companies across Canada. Mr. Geyer is also on the Board of Governors of the British Columbia Science World, where he is actively involved in the establishment of a new life sciences gallery called ‘BodyWorks’.

David Goodkin, MD, FACP
Director

Dr. Goodkin is Acting Executive Vice President and Chief Medical Officer of privately held biopharmaceutical company Xenon Pharmaceuticals Inc., a position he has held since February 2007. From August 2002 to January 2007, he was Senior Vice President, Development and Chief Medical Officer of ICOS Corporation, source of the blockbuster impotence drug Cialis. ICOS was acquired by Eli Lilly for $2.1 billion in 2006. Prior to ICOS, Dr. Goodkin spent 10 years at Amgen Inc. where he held a number of senior management positions. As Vice President, Clinical Research at Amgen he supervised team leaders for all clinical programs and was responsible for the international design, implementation, interpretation and reporting of clinical trials.

Dr. Goodkin received a bachelor of arts degree from Dartmouth College and a medical degree from the State University of New York. He completed his residency in internal medicine at the University of Miami School of Medicine and fellowship training in nephrology at Temple University Health Sciences Center and Albert Einstein Medical Center. From 1985 until 2002, Dr. Goodkin was an attending physician specializing in nephrology and internal medicine.

Jim Heppell, LLB
Director

Mr. Jim Heppell is President and Fund Manager of BC Advantage (VCC) Funds Inc., a venture fund focused on financing early stage life science and technology companies. He has a Bachelor of Science degree in Microbiology and an LL.B. from the University of British Columbia, and focuses his efforts on the Fund's life science investments.

Over the last twenty years, Mr. Heppell has acted as a director, officer or advisor to approximately one-third of the life science companies that have spun out of British Columbia universities. He has also worked with a number of US life science companies. Mr. Heppell is the Chairman of the Board of Inovio Biomedical (AMEX: INO) and a director of Protox Therapeutics (TSX-V: PRX).

Mr. Heppell is a past director of BC Biotech and a past member of the Securities Policy Advisory Committee to the British Columbia Securities Commission. Over the years, he has written a number of articles and taught numerous courses on corporate finance and corporate governance issues as they relate to life science companies. Mr. Heppell currently writes a regular column for Business in Vancouver on the Business of Biotechnology.

Pierre Leduc
Director

Mr. Leduc is principal of Leduc Associates Management Consultants, a firm specializing in biotechnology companies. Prior to forming his consultancy, he served as President and CEO of Neurostream Technologies Inc., a privately held medical device company developing implantable neurotechnology devices. Mr. Leduc was also Chairman of Xillix Technologies Corp., a TSX-listed medical device company engaged in the manufacture of endoscopic devices for the early detection of cancer.

Earlier in his career, Mr. Leduc had a 20-year association with Baxter Corporation in many executive capacities, including President of Baxter Corporation Canada, Area Managing Director, Australia-New Zealand and Marketing Manager, Americas-Pacific, Baxter World Trade Corp., Deerfield, Illinois.

Mr. Leduc currently serves on the Board of Directors of Providence Health Care and Ondine Biopharma Inc. (TSX: OBP) of Vancouver, BC and Novx Systems Inc. of Markham, Ontario.

Zeid Mohamedali, MD, PhD, FRCSC
Director

Dr. Mohamedali brings to the Board of Urodynamix valuable expertise in urology and the application of medical technology to clinical practice. He is a consulting urologist at several hospitals in British Columbia with over 20 years of experience in medical research and clinical practice specializing in oncology and urology.

A Fellow of the Royal College of Physicians and Surgeons, Dr. Mohamedali is board certified in Urology by the Medical Council of Canada. He has received numerous awards and honors for his research from the American Urological Association, the Canadian Cancer Society, the Natural Sciences and Engineering Research Council of Canada and the Medical Research Council of Canada, and received his MD and PhD degrees from the Faculty of Medicine at the University of British Columbia.

Tanner Philp, CA
Corporate Secretary

Mr. Philp currently serves as Chief Financial Officer and Partner of Lions Capital Corp., the fund manager of BC Advantage Funds (VCC) Ltd., a venture capital fund that invests in emerging technology and life science companies. Mr. Philp is a Director of Vigil Health Solutions Inc. and an advisor to a number of technology companies where he works to maximize value for investors. He specializes in working with early-stage public and private companies on business strategy development, funding, mergers and acquisitions and corporate partnering.

Mr. Philp is a Chartered Accountant who began his career with KPMG Vancouver and subsequently worked for KPMG London (UK) where he specialized in providing consulting and corporate finance services. He holds a Bachelor of Business Administration in Finance from Simon Fraser University.